Pilot study on the effects of intravesical oxybutynin hydrochloride instillations on the validity of doping control urine samples (2023)

Walpurgis, K., Scheiff, A. B., Welz, M., Müller-Reul, J., Webborn, N., Görgens, C., Guddat, S., Fußhöller, G., Dib, J. (2019). Pilot study on the effects of intravesical oxybutynin hydrochloride instillations on the validity of doping control urine samples. Drug testing and analysis, 11(11-12), 1755-1760. https://doi.org/10.1002/dta.2705

Walpurgis, Katja ; Scheiff, Anja B. ; Welz, Meike et al. / Pilot study on the effects of intravesical oxybutynin hydrochloride instillations on the validity of doping control urine samples. In: Drug testing and analysis. 2019 ; Vol. 11, No. 11-12. pp. 1755-1760.

@article{58196ce99f6443d695634b2afa896526,

title = "Pilot study on the effects of intravesical oxybutynin hydrochloride instillations on the validity of doping control urine samples",

abstract = "Abstract According to class M2.1 of the World Anti-Doping Agency (WADA) Prohibited List, the manipulation of doping control urine samples to alter their integrity and validity is prohibited both in- and out-of-competition. However, some paraplegic athletes with an overactive bladder need to be regularly treated with anti-cholinergic and anti-spasmodic drugs such as oxybutynin, which are often administered intravesically to reduce the substantial side effects observed after oral application. So far, it remains unclear whether such bladder instillations have a negative impact on analytical procedures and thus represent an anti-doping rule violation. Within this pilot study, urine samples were collected from five paraplegic athletes before and after an intravesical oxybutynin hydrochloride instillation. The samples were routinely tested for the presence of performance-enhancing drugs and afterwards fortified with 25 model compounds representing different classes of doping agents (anabolic agents, cannabinoids, diuretics, glucocorticoids, hormone and metabolic modulators, and stimulants) at low and medium concentrations. Additionally, the pH value and specific gravity were measured and the presence of oxybutynin was qualitatively determined by gas chromatography−mass spectrometry (GC–MS). In initial testing procedures, all samples were tested negative. Oxybutynin was present in most of the samples but found to have no significant effect on the detectability of the 25 model compounds subsequently added to each urine specimen. Therefore, it can be concluded that intravesical instillations with oxybutynin hydrochloride do not alter the integrity and validity of doping control urine samples.",

keywords = "disability sports, doping, intravesical instillations, manipulation, oxybutynin",

author = "Katja Walpurgis and Scheiff, {Anja B.} and Meike Welz and Jutta M{\"u}ller-Reul and Nick Webborn and Christian G{\"o}rgens and Sven Guddat and Gregor Fu{\ss}h{\"o}ller and Josef Dib and Mario Thevis",

year = "2019",

month = nov,

day = "1",

doi = "10.1002/dta.2705",

language = "English",

volume = "11",

pages = "1755--1760",

journal = "Drug testing and analysis",

issn = "1942-7603",

publisher = "John Wiley & Sons, Ltd",

number = "11-12",

note = "Manfred Donike Workshop on Doping Analysis ; Conference date: 17-02-2019 Through 22-02-2019",

}

Walpurgis, K, Scheiff, AB, Welz, M, Müller-Reul, J, Webborn, N, Görgens, C, Guddat, S, Fußhöller, G, Dib, J 2019, 'Pilot study on the effects of intravesical oxybutynin hydrochloride instillations on the validity of doping control urine samples', Drug testing and analysis, vol. 11, no. 11-12, pp. 1755-1760. https://doi.org/10.1002/dta.2705

Pilot study on the effects of intravesical oxybutynin hydrochloride instillations on the validity of doping control urine samples. / Walpurgis, Katja; Scheiff, Anja B.; Welz, Meike et al.

In: Drug testing and analysis, Vol. 11, No. 11-12, 01.11.2019, p. 1755-1760.

Publication: Contribution to journal › Conference article in journal › Research › peer-review

TY - JOUR

T1 - Pilot study on the effects of intravesical oxybutynin hydrochloride instillations on the validity of doping control urine samples

AU - Walpurgis, Katja

AU - Scheiff, Anja B.

AU - Welz, Meike

AU - Müller-Reul, Jutta

AU - Webborn, Nick

AU - Görgens, Christian

AU - Guddat, Sven

AU - Fußhöller, Gregor

AU - Dib, Josef

AU - Thevis, Mario

N1 - Conference code: 37

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Abstract According to class M2.1 of the World Anti-Doping Agency (WADA) Prohibited List, the manipulation of doping control urine samples to alter their integrity and validity is prohibited both in- and out-of-competition. However, some paraplegic athletes with an overactive bladder need to be regularly treated with anti-cholinergic and anti-spasmodic drugs such as oxybutynin, which are often administered intravesically to reduce the substantial side effects observed after oral application. So far, it remains unclear whether such bladder instillations have a negative impact on analytical procedures and thus represent an anti-doping rule violation. Within this pilot study, urine samples were collected from five paraplegic athletes before and after an intravesical oxybutynin hydrochloride instillation. The samples were routinely tested for the presence of performance-enhancing drugs and afterwards fortified with 25 model compounds representing different classes of doping agents (anabolic agents, cannabinoids, diuretics, glucocorticoids, hormone and metabolic modulators, and stimulants) at low and medium concentrations. Additionally, the pH value and specific gravity were measured and the presence of oxybutynin was qualitatively determined by gas chromatography−mass spectrometry (GC–MS). In initial testing procedures, all samples were tested negative. Oxybutynin was present in most of the samples but found to have no significant effect on the detectability of the 25 model compounds subsequently added to each urine specimen. Therefore, it can be concluded that intravesical instillations with oxybutynin hydrochloride do not alter the integrity and validity of doping control urine samples.

AB - Abstract According to class M2.1 of the World Anti-Doping Agency (WADA) Prohibited List, the manipulation of doping control urine samples to alter their integrity and validity is prohibited both in- and out-of-competition. However, some paraplegic athletes with an overactive bladder need to be regularly treated with anti-cholinergic and anti-spasmodic drugs such as oxybutynin, which are often administered intravesically to reduce the substantial side effects observed after oral application. So far, it remains unclear whether such bladder instillations have a negative impact on analytical procedures and thus represent an anti-doping rule violation. Within this pilot study, urine samples were collected from five paraplegic athletes before and after an intravesical oxybutynin hydrochloride instillation. The samples were routinely tested for the presence of performance-enhancing drugs and afterwards fortified with 25 model compounds representing different classes of doping agents (anabolic agents, cannabinoids, diuretics, glucocorticoids, hormone and metabolic modulators, and stimulants) at low and medium concentrations. Additionally, the pH value and specific gravity were measured and the presence of oxybutynin was qualitatively determined by gas chromatography−mass spectrometry (GC–MS). In initial testing procedures, all samples were tested negative. Oxybutynin was present in most of the samples but found to have no significant effect on the detectability of the 25 model compounds subsequently added to each urine specimen. Therefore, it can be concluded that intravesical instillations with oxybutynin hydrochloride do not alter the integrity and validity of doping control urine samples.

KW - disability sports

KW - doping

KW - intravesical instillations

KW - manipulation

KW - oxybutynin

UR - https://www.mendeley.com/catalogue/af6577d0-33ca-3e59-a481-c248accf9f42/

U2 - 10.1002/dta.2705

DO - 10.1002/dta.2705

M3 - Conference article in journal

SN - 1942-7603

VL - 11

SP - 1755

EP - 1760

JO - Drug testing and analysis

JF - Drug testing and analysis

IS - 11-12

T2 - Manfred Donike Workshop on Doping Analysis

Y2 - 17 February 2019 through 22 February 2019

ER -

Walpurgis K, Scheiff AB, Welz M, Müller-Reul J, Webborn N, Görgens C et al. Pilot study on the effects of intravesical oxybutynin hydrochloride instillations on the validity of doping control urine samples. Drug testing and analysis. 2019 Nov 1;11(11-12):1755-1760. doi: 10.1002/dta.2705